[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Christian Juhl Terkelsen\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100552202",false,"NCT06470022","Comparison of Evolut FX Versus Sapien 3 Ultra Resilia.","Randomized Comparison of Evolut FX Versus Sapien 3 Ultra Resilia. The Compare-TAVI 2 Trial","COMPARE-TAVI","Inclusion Criteria:\n\n1. Patient more than 18 years of age.\n2. Patient eligible for both Evolut FX and Edwards Sapien 3 Ultra Resilia according to a TAVI heart team conference.\n3. The center experience for each of the valves considered should be more than 15 cases a year, and the treating physician should have implanted at least 15 of each valve used in the trial.\n4. The center volume should be more than 75 cases a year.\n5. The patient has given signed informed consent.\n6. TAVI performed via the femoral artery.\n\nExclusion Criteria:\n\nNone",true,"ALL","18 Years",{"count":20,"type":21},1346,"ESTIMATED","INTERVENTIONAL",[24],"NA","To compare outcome in patients randomized to treatment with Evolut FX versus Sapien 3 Ultra Resilia.",[27],"Aortic Stenosis","RECRUITING","2026-04-22",{"date":31,"type":32},"2026-04-28","ACTUAL",{"date":34,"type":32},"2024-08-09",{"date":36,"type":21},"2036-12-01",{"name":38,"class":39},"Christian Juhl Terkelsen","OTHER",""]